Treatments for IgA Nephropathy
Treatments for IgA nephropathy fall into several major groups. Some treatments lower pressure inside the kidney filters, some reduce inflammation, and others directly target the immune pathways that drive the disease. Most people receive a combination of these approaches based on kidney function, amount of protein in the urine, and overall health.
The 2025 KDIGO guidelines indicate that persistent proteinuria of ā„ 0.5 g/day or a UPCR (urine protein/creatinine ratio) of ā„ 0.5 g/g signals increased risk of progressive loss of kidney function, whether or not treatment has already begun. The guideline identifies a treatment goal of less than 0.5 g/day and ideally less than 0.3 g/day, or a UPCR of less than 0.3 g/g. Thus, finding the right medication or medications to reduce proteinuria is an important part of lowering the risk of progressive kidney disease. Proteinuria is also a surrogate measure, and not every treatment has yet demonstrated a long-term reduction in kidney failure or death.
Table of Contents
The Two-Pronged Approach to Managing IgA Nephropathy
According to KDIGO, a worldwide organization developing and implementing evidence-based clinical practice guidelines in kidney disease, effective treatment for IgA nephropathy involves two connected goals.
One is slowing the progression of chronic kidney disease (CKD) through measures that lower proteinuria, protect the kidney filters, and reduce ongoing injury, largely considered supportive care. The other, requiring IgA nephropathy-specific medicines, is reducing the production of galactose-deficient IgA1 (Gd-IgA1) and calming the immune pathways that cause inflammation in the kidneys.
Different treatments work on different parts of this strategy. Supportive therapies such as RAAS blockade, SGLT2 inhibitors, blood pressure control, and lifestyle measures focus on preserving kidney function over time. Medicines that target the immune system aim to reduce the upstream drivers of Gd-IgA1 and its immune effects.
Most people benefit from a combination of these approaches.
RAAS Blockade
The renin-angiotensin-aldosterone system (RAAS) helps control blood pressure and pressure inside the kidney filters. Medicines such as ACE inhibitors (angiotensin converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) lower this internal pressure and reduce protein loss in the urine. Even though they are not approved specifically "for IgA nephropathy" on the label, they are a standard part of care for most people with IgA nephropathy because they help protect kidney function over time.
Updated:
SGLT2 Inhibitors
SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors) were first developed to treat diabetes, but they also protect the kidneys. They reduce stress on the filtering units, lower protein leakage, and can slow the decline in kidney function in people with chronic kidney disease. In IgA nephropathy, SGLT2 inhibitors are often added on top of RAAS blockade when kidney function and other factors make their use appropriate, even if the drug label does not mention IgA nephropathy by name. The exact combination depends on the specific IgA nephropathy medicine and its label.
In the peer-reviewed, prespecified IgA nephropathy subgroup analysis of the phase 3 DAPA-CKD trial (270 participants), dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) by 26% relative to placebo (p < 0.001). Annualized eGFR slopes were -3.5 versus -4.7 mL/min/1.73 m2/year over a median 2.1 years, a numerical difference of +1.2 (95% CI -0.12 to 2.51) that was not statistically significant.
Updated:
Mineralocorticoid Receptor Antagonists
Finerenone (Kerendia) is an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), a kidney-protection medicine that blocks a hormone pathway involved in inflammation and scarring. In the phase 3 FIND-CKD trial, finerenone slowed kidney-function decline in people with CKD without diabetes. A Kidney Week 2026 conference abstract reported an exploratory IgA nephropathy subgroup analysis of 416 FIND-CKD participants: the urine protein-to-creatinine ratio (UPCR) was 51% lower than placebo at month 12. The annualized eGFR slope difference was +0.6 mL/min/1.73 m2/year, but its confidence interval included no difference, so the eGFR result was not statistically significant and a kidney-function benefit in this subgroup remains uncertain.
The FDA accepted Bayer's application to expand finerenone's use to CKD without diabetes in October 2026; that indication remains under review. Finerenone is not approved specifically for IgA nephropathy. Whether it fits alongside other kidney-protection medicines depends on kidney function, potassium, and the rest of the treatment plan, with monitoring for high potassium particularly important.
Updated:
IgA Nephropathy-Specific Medicines
Seven medicines are now approved in the United States specifically for adults with primary IgA nephropathy who are at risk of disease progression: Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact, Trutakna, and Ultomiris. Three have traditional FDA approval based on confirmatory kidney-function data, while four have accelerated approval based primarily on proteinuria reduction, with continued approval contingent on confirmation of long-term clinical benefit. These medicines are not interchangeable, and they are not all used in the same way with RAAS blockade or other supportive therapies. Treatment choices should follow the individual product label and the patient's kidney function, blood pressure, pregnancy risk, and infection risk.
Targeted enteric-release corticosteroid
- Generic: budesonide delayed-release capsules / targeted-release formulation budesonide (TRF-budesonide)
- Brand: Tarpeyo; marketed as Kinpeygo in some regions
- Mechanism: a corticosteroid designed to release mainly in the lower small intestine, where a large part of the immune system involved in IgA nephropathy sits.
- Regulatory status (US): received accelerated approval in 2021 to reduce proteinuria in adults with primary IgA nephropathy; the FDA later granted full (traditional) approval in 2023 after confirmatory data.
- Key data: in the peer-reviewed phase 3 NefIgArd trial, 24-hour UPCR was 27% lower than placebo at month 9 (p=0.0005). The time-weighted average eGFR change over two years was -2.47 versus -7.52 mL/min/1.73 m2, a treatment difference of +5.05 mL/min/1.73 m2 (p < 0.0001). Treatment lasted 9 months, followed by 15 months off treatment.
- Updated:
Viatris is also developing VR-205, a targeted-release budesonide formulation of Nefecon, for adults with IgA nephropathy in Japan. Its phase 3 Japanese study reported positive top-line results in June 2026, and the company is targeting a Japanese New Drug Application by the end of 2026. VR-205 is not a separate U.S.-approved mechanism; it is a regional formulation and development program.
Dual endothelin / angiotensin receptor blocker
- Generic: sparsentan
- Brand: Filspari
- Mechanism: blocks both the endothelin A receptor and the angiotensin II type 1 receptor, directly targeting glomerular injury and protein leakage.
- Regulatory status (US): initially received accelerated approval, then in 2024 gained full FDA approval to slow kidney function decline and reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression.
- Key data: in the peer-reviewed, randomized phase 3 PROTECT trial, 24-hour UPCR fell 49.8% from baseline with sparsentan versus 15.1% with irbesartan at week 36, a 41% relative reduction (p < 0.0001). At week 110, reductions were 42.8% versus 4.4%. The chronic eGFR slopes from weeks 6 to 110 were -2.7 versus -3.8 mL/min/1.73 m2/year (difference +1.1; p=0.037).
- Important treatment note: because Filspari combines endothelin and angiotensin-receptor blockade, its current label instructs clinicians to discontinue RAAS inhibitors and endothelin-receptor antagonists before starting Filspari and contraindicates concomitant use of ARBs, ERAs, or aliskiren.
- Additional findings: a Kidney Week 2026 analysis of PROTECT found significantly greater reductions in urinary sCD163, BAFF, C5b-9, and IL-6 with sparsentan than with irbesartan at week 110. These biomarker findings do not establish reversal of kidney scarring.
- Additional findings: a Kidney Week 2026 spatial-transcriptomics analysis of SPARTAN biopsy tissue associated sparsentan treatment with reduced complement-associated transcriptional activity and attenuation of fibroblast-rich inflammatory microenvironments. These molecular findings do not establish histological reversal of fibrosis or tubular atrophy.
- Updated:
Selective endothelin A receptor antagonist
- Generic: atrasentan
- Brand: Vanrafia
- Mechanism: selectively blocks the endothelin A receptor, which is involved in narrowing blood vessels and promoting kidney damage in proteinuric kidney disease.
- Regulatory status (US): received FDA accelerated approval in April 2025 to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. Novartis completed U.S. and EU submissions for traditional approval in 2026. Vanrafia remains under accelerated approval in the U.S. pending FDA action.
- Key data: the peer-reviewed phase 3 week 36 interim analysis found that 24-hour UPCR fell 38.1% from baseline with atrasentan versus 3.1% with placebo (36.1% relative benefit; p < 0.001). The peer-reviewed final 2.5-year ALIGN analysis showed an annualized total eGFR slope of -2.7 versus -4.1 mL/min/1.73 m2/year (difference +1.4; nominal p=0.003). The prespecified week 136 eGFR change endpoint was +2.4 mL/min/1.73 m2 versus placebo and did not reach statistical significance (p=0.057).
- Additional findings: an exploratory East Asian ALIGN subgroup analysis (138 participants) reported an annualized eGFR slope difference of +1.07 mL/min/1.73 m2/year versus placebo (95% CI -0.29 to 2.44), which included no difference. The overall phase 3 findings remain the stronger evidence.
- Updated:
Complement pathway inhibitor
- Generic: iptacopan
- Brand: Fabhalta
- Mechanism: an oral inhibitor of complement factor B, targeting the alternative complement pathway, which is thought to contribute to kidney injury in IgA nephropathy.
- Regulatory status (US): received FDA accelerated approval in August 2024 to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. In July 2026, the FDA granted traditional approval to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression, based on final phase 3 data showing slower decline compared with placebo.
- Key data: in the peer-reviewed final 24-month phase 3 APPLAUSE-IgAN results, 24-hour UPCR was 38.3% lower than placebo at month 9 (p < 0.001). Annualized eGFR slopes were -3.10 versus -6.12 mL/min/1.73 m2/year (difference +3.02; p < 0.001), and the composite kidney-failure endpoint occurred in 21.4% versus 33.5% of participants (hazard ratio 0.57; p=0.003).
- Updated:
Complement C5 inhibitor
- Generic: ravulizumab-cwvz
- Brand: Ultomiris
- Mechanism: a long-acting monoclonal antibody that blocks complement protein C5, reducing terminal complement activation and the inflammation and injury it can cause in the kidney.
- Regulatory status (US): received FDA accelerated approval in October 2026 to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Treatment is given by intravenous infusion, with maintenance doses every eight weeks after the initial loading schedule.
- Key data: AstraZeneca-reported interim phase 3 I CAN results showed a statistically significant 43.4% reduction in 24-hour UPCR relative to placebo at week 34. The trial continues to assess eGFR through week 106; long-term kidney-function benefit has not yet been established.
- Important treatment note: C5 inhibition increases the risk of serious meningococcal infections. Treatment requires vaccination planning and participation in a restricted safety program (REMS); vaccination does not eliminate the infection risk.
- Updated:
APRIL-targeting monoclonal antibody
- Generic: sibeprenlimab-szsi
- Brand: Voyxact
- Mechanism: a monoclonal antibody that targets APRIL (A Proliferation-Inducing Ligand), a signaling protein involved in the abnormal IgA immune response that drives IgA nephropathy.
- Regulatory status (US): received FDA accelerated approval in November 2025 to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Otsuka completed its rolling supplemental BLA submission seeking traditional approval in October 2026. Voyxact remains under accelerated approval unless and until the FDA grants that supplemental application.
- Key data: Otsuka reported final two-year phase 3 VISIONARY results showing annualized eGFR slopes of +0.3 versus -4.2 mL/min/1.73 m2/year with placebo. A composite kidney-function decline or kidney-failure outcome occurred in 1 versus 28 participants. By month 24, 24-hour UPCR had fallen 61.3% from baseline.
- Updated:
Dual BAFF/APRIL inhibitor
- Generic: atacicept-vymj
- Brand: Trutakna
- Mechanism: a fusion protein that blocks both BAFF and APRIL, aiming to reduce production of Gd-IgA1 and other harmful antibodies.
- Regulatory status (US): received FDA accelerated approval in July 2026 to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Trutakna is injected subcutaneously once weekly. Vera plans to seek traditional approval; Trutakna remains under accelerated approval unless and until the FDA grants that supplemental application.
- Key data: the peer-reviewed final 104-week phase 3 ORIGIN 3 results showed an annualized eGFR slope of -0.6 versus -5.6 mL/min/1.73 m2/year with placebo. The composite kidney-progression outcome occurred in 11 versus 38 patients, corresponding to a 76% lower hazard than placebo.
- Important treatment note: because Trutakna suppresses the immune system, the FDA label warns about infections and reduced immune responses to vaccines, including avoidance of live vaccines during treatment.
- Additional findings: an open-label, uncontrolled interim analysis of the phase 2 PIONEER trial included 94 adults with IgAN, including people with eGFR below 30, moderate (UPCR 0.5-1.0 g/g) or very high proteinuria (ā„5 g/g), IgA vasculitis nephritis, or recurrent disease after transplantation-populations excluded from ORIGIN 2b/3. Mean change from baseline in 24-hour UPCR was -34% (SE 3.2) at week 12 and -41% (SE 7.7) at week 24, similar across the IgAN cohorts. These uncontrolled changes are not placebo-adjusted. No new safety signals or clinically significant hypogammaglobulinemia were observed.
- Additional findings: PIONEER is also expanding to children aged 2 to under 18 years with IgAN or IgA vasculitis nephritis. No pediatric efficacy results have been reported.
- Updated:
Beneficial Lifestyle Changes
Alongside these drug treatments, other measures are important for nearly everyone with IgA nephropathy. These include carefully controlling blood pressure, limiting salt intake, managing cholesterol, treating anemia when present, maintaining a healthy weight, stopping smoking, and staying current with recommended vaccinations. These steps do not replace disease-specific medicines, but they work together with them to protect kidney function and overall health over time.
Updated:
Clinical Trials
Clinical trials give people access to investigational IgA nephropathy treatments that are not yet widely available. Many trials study medicines that target specific parts of the immune system or complement system involved in IgA production and kidney injury. Others test new ways to reduce proteinuria or protect kidney function. Participation is voluntary, and each trial has its own eligibility criteria based on kidney function, protein levels, and other health factors. Trials help researchers confirm how well new therapies work and whether they can slow long-term kidney damage. For some patients, a clinical trial may offer an option when standard treatments are not enough. Participation also contributes evidence that may help future patients, including people who cannot enroll because of health criteria, location, or financial constraints.
Most of the medicines listed below are not approved for routine use and are still undergoing evaluation from preclinical development through phase 3 studies. Where a medicine has a regional approval, that status is stated in its entry. These therapies target different parts of the immune system, complement system, disease-driving IgA, or kidney-injury pathways involved in IgA nephropathy.
To see a list of open clinical trials for IgA nephropathy, refer to the IgA Nephropathy Foundation's up-to-date listing.
How to Think About These Therapies
Because many of these treatments are still experimental, the most important questions are whether they can reliably lower proteinuria, help stabilize kidney function, and maintain an acceptable safety profile over time. Some medicines-such as telitacicept, povetacicept, felzartamab, and mezagitamab-already have encouraging phase 2-3 results. Others, such as BHV-1400, CLYM116, ARGX-121, and PS-002, are earlier in development but aim directly at underlying disease mechanisms.
Access to these investigational therapies is generally limited to clinical trials, and results from ongoing studies will determine which become future treatment options. Decisions about trial participation should consider kidney function, current treatment response, the demands of trial visits, and personal goals.
Categories of Investigational and Regionally Approved Therapies
The following investigational or regionally approved medicines are grouped by the main part of the immune system they target:
1. BAFF/APRIL-Targeting Biologics
These drugs try to interrupt the overactive B-cell signaling that leads to production of disease-causing IgA and Gd-IgA1. They focus on BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two key signals that help B cells survive and mature. Medicines in this section remain investigational unless otherwise noted.
Povetacicept (long-acting dual BAFF/APRIL biologic)
- Mechanism: a long-acting agent given by subcutaneous injection (typically every 4 weeks) that blocks both BAFF and APRIL.
- Key data: the peer-reviewed, prespecified week 36 interim analysis of the ongoing phase 3 RAINIER trial, published in the New England Journal of Medicine in October 2026, showed 24-hour UPCR fell 52.0% from baseline with povetacicept and 4.3% with placebo, an adjusted between-group difference of -49.8 percentage points (95% CI -58.6 to -39.2; p < 0.001). In an exploratory analysis reported by Vertex, 42.2% of participants had 24-hour UPCR below 0.5 g/g, compared with 6.2% on placebo.
- Status: the FDA accepted Vertex's BLA for accelerated approval in June 2026 and the application remains under priority review, with Vertex reaffirming the PDUFA target action date of November 30, 2026 on November 2, 2026. The phase 3 trial remains ongoing to assess longer-term kidney outcomes, and povetacicept is not yet approved for IgA nephropathy.
Updated:
Mechanism: a fusion protein that binds and neutralizes both BAFF and APRIL, similar in concept to atacicept but with a different structure.
- Key data: company-reported final 104-week phase 3 TELIGAN results showed an annualized eGFR slope of -0.6 versus -5.7 mL/min/1.73 m2/year with placebo, a treatment difference of +5.1 mL/min/1.73 m2/year. At week 104, 24-hour UPCR fell 60.3% from baseline, compared with a 0.9% increase with placebo.
- Status: China's NMPA granted conditional approval for IgA nephropathy in June 2026. Telitacicept is not approved for IgA nephropathy by the U.S. FDA.
- Updated:
CLYM116 / MIL116 (anti-APRIL "sweeper" antibody)
- Mechanism: an anti-APRIL antibody designed to bind, release, and promote degradation of APRIL rather than simply block it. The goal is to produce deep and durable suppression with less frequent dosing.
- Key data: Climb Bio reported October 2026 phase 1 data in healthy volunteers, including an estimated half-life of about 33 days. A single dose of at least 480 mg maintained at least 90% free APRIL suppression through week 12; an 800 mg dose reduced Gd-IgA1 by about 70% and total IgA by about 60% at week 12. These biomarker findings do not establish efficacy in IgA nephropathy patients.
- Status: the phase 2 NAVIGATE-2 study is enrolling; initial data are anticipated in the first half of 2027, and phase 3 initiation is anticipated in 2027. The public trial record uses the development name MIL116. It is not approved for IgA nephropathy.
- Updated:
JADE101 (anti-APRIL monoclonal antibody)
- Mechanism: a monoclonal antibody designed to selectively block APRIL, aiming to reduce pathogenic IgA production while allowing infrequent subcutaneous dosing.
- Key data: Jade Biosciences reported positive interim phase 1 data, including potent APRIL suppression and a dosing profile intended to support infrequent subcutaneous administration.
- Status: the JUNIPER phase 2 trial in IgA nephropathy is recruiting, with interim data expected in the second quarter of 2027. The EVERGREEN phase 3 trial is expected to begin in the fourth quarter of 2026, with about 420 participants planned and up to 60 more in exploratory cohorts. Maintenance dosing will be every 8 or 12 weeks, and the primary endpoint is UPCR change at month 12. JADE101 is not approved for IgA nephropathy.
- Updated:
Zigakibart (BION-1301, anti-APRIL monoclonal antibody)
- Mechanism: a monoclonal antibody that blocks APRIL alone, aiming to reduce survival of plasma cells that make Gd-IgA1.
- Key data: a Kidney Week 2026 conference abstract reported that at week 124, 64% of evaluable participants had urinary protein excretion below 0.5 g/day in an open-label, single-arm phase 2 study. The uncontrolled design cannot establish comparative benefit.
- Status: the BEYOND phase 3 trial is underway to confirm efficacy and safety in a larger, global IgA nephropathy population. A separate phase 3b LUMINA IgAN trial plans to randomize about 340 participants to zigakibart plus atrasentan or zigakibart plus placebo; its primary endpoint is change in proteinuria at week 36. This is a trial-design report, with no combination efficacy results yet.
- Updated:
2. Complement-Pathway Inhibitors
These drugs target the complement system, which amplifies inflammation and tissue injury once immune complexes deposit in the kidney. Different agents act at different "checkpoints" in the complement cascade.
SGB-9768 (liver-targeted siRNA to complement C3)
- Mechanism: a GalNAc-conjugated small interfering RNA designed to reduce liver production of complement C3.
- Key data: a Kidney Week 2026 conference abstract reported that, in a small, open-label, uncontrolled phase 2 study of 30 participants with IgA nephropathy, 24-hour UPCR fell from baseline by 58.6% in the 300 mg group and by 74.1% in the 600 mg group. The study had no placebo group, so these early results do not establish comparative efficacy.
- Status: the phase 2 study has reported results; SGB-9768 remains investigational and is not approved for IgA nephropathy.
- Updated:
RG002C0106 (Rigerna Therapeutics; C3-targeting siRNA)
- Mechanism: a small interfering RNA designed to reduce complement C3 production, aiming for sustained complement modulation with infrequent dosing.
- Key data: a Kidney Week 2026 late-breaking phase 2 abstract reported interim results from 34 adults with biopsy-confirmed IgA nephropathy randomized 4:1 to RG002C0106 regimens or placebo. At week 12, placebo-adjusted mean reductions in 24-hour UPCR were 50% in the low-dose regimen and 52%-67% across three higher-dose regimens. Proteinuria responses were reported by week 2, with improvement in hematuria by week 12. No serious adverse events or serious infections were reported at the analysis cutoff.
- Status: investigational phase 2 therapy. The study includes a 24-week randomized period followed by a 96-week open-label extension. The abstract reports interim findings through week 12; 24-week efficacy results and long-term eGFR benefit remain unestablished.
- Additional findings: this small study's 4:1 allocation among 34 adults implies approximately seven placebo recipients. Findings are available as a conference abstract only.
- Updated:
Ebribafusp (AKB-097 / ADX-097; tissue-targeted complement inhibitor)
- Mechanism: an anti-C3d factor H fusion protein designed to localize complement inhibition to affected tissues, including the kidney, while preserving complement activity in the blood.
- Key data: a completed phase 1 study in healthy volunteers found that weekly subcutaneous dosing achieved the company's targeted tissue-exposure profile and was generally well tolerated. These findings do not establish efficacy in IgA nephropathy.
- Status: Akebia dosed the first patient in an open-label phase 2 basket trial in September 2026 for IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The study plans to enroll up to 30 patients and report initial data in 2027. It is not approved for IgA nephropathy.
- Updated:
Cemdisiran (siRNA to C5)
- Mechanism: a small interfering RNA (siRNA) drug that reduces production of C5 in the liver, lowering circulating C5 and dampening terminal complement activity.
- Key data: in a peer-reviewed, randomized, double-blind phase 2 trial of 31 patients, placebo-adjusted reductions at week 32 were 37.4% in 24-hour UPCR and 45.8% in spot UPCR. The 90% confidence interval for the primary 24-hour UPCR result included no difference.
- Status: the IgA nephropathy phase 2 study was subsequently terminated and is no longer recruiting. Cemdisiran remains investigational for IgA nephropathy.
- Updated:
Sefaxersen (RO7434656, IONIS-FB-LRx; antisense to complement factor B)
- Mechanism: an antisense oligonucleotide that lowers production of factor B, a key component of the alternative complement pathway.
- Key data: Roche-reported interim phase 3 IMAgINATION results showed that 24-hour UPCR was 43.1% lower than placebo at week 37.
- Status: the trial continues to assess kidney function through week 105. The interim proteinuria findings do not yet establish long-term kidney-function benefit, and sefaxersen is not approved for IgA nephropathy.
- Updated:
HSK39297 (oral complement factor B inhibitor)
- Mechanism: an oral small-molecule inhibitor of complement factor B, intended to reduce alternative-pathway complement activation.
- Key data: a WCN 2026 conference e-poster reported interim week 12 results from a randomized, double-blind phase 2 trial of 87 patients. 24-hour UPCR fell 48.2%-52.5% from baseline across dose groups versus 5.3% with placebo; placebo-adjusted reductions were 45.3%-49.8% (pā¤0.0001). The poster described eGFR as stable but did not report quantitative eGFR results.
- Status: phase 2 data collection is complete, an open-label phase 2 long-term extension study is recruiting participants who completed the earlier phase 2 trial, and a separate phase 3 trial in primary IgA nephropathy is recruiting. It is not approved for IgA nephropathy.
- Updated:
ADX-038 (siRNA to complement factor B)
- Mechanism: a small interfering RNA (siRNA) therapy designed to silence complement factor B in the liver and selectively suppress alternative-pathway complement activity.
- Key data: a phase 1 study in healthy volunteers found that a single dose produced near-complete alternative-pathway inhibition for about six months while leaving classical-pathway activity unchanged. The study was generally well tolerated, but no patient efficacy data in IgA nephropathy have been reported.
- Status: phase 2 studies are recruiting in IgA nephropathy and other complement-mediated kidney diseases, including a Chinese study evaluating ADX-038 alone and in combination with telitacicept. It is not approved for IgA nephropathy.
- Updated:
HS-10542 (oral complement factor B inhibitor)
- Mechanism: an oral, once-daily small-molecule inhibitor of complement factor B, intended to suppress alternative- pathway activation.
- Key data: Hansoh reported phase 1 healthy-volunteer data showing a favorable early safety and pharmacokinetic profile with alternative-pathway inhibition. No patient efficacy data in IgA nephropathy have been reported.
- Status: a phase 2 dose-ranging study in primary IgA nephropathy is registered but listed as not yet recruiting. It is not approved for IgA nephropathy.
- Updated:
NTQ5082 (oral complement factor B inhibitor)
- Mechanism: an oral small-molecule inhibitor of complement factor B designed to block the alternative complement pathway.
- Key data: a phase 2 study is evaluating changes in UPCR, eGFR, serum creatinine, and related urine markers in adults with primary IgA nephropathy.
- Status: the phase 2 study is listed as not yet recruiting. NTQ5082 is not approved for IgA nephropathy.
- Updated:
SLN12140 (selective complement inhibitor)
- Mechanism: a next-generation complement inhibitor designed for selective pathway suppression. Public materials do not yet provide enough detail to describe the target more specifically.
- Key data: no patient efficacy data in IgA nephropathy have been reported.
- Status: a randomized phase 2 study in adults with primary IgA nephropathy in China is listed as not yet recruiting. It is not approved for IgA nephropathy.
- Updated:
BW-40202 (siRNA to complement factor B)
- Mechanism: a small interfering RNA (siRNA) therapy designed to silence CFB mRNA in the liver, lowering serum complement factor B levels and suppressing alternative-pathway activity.
- Key data: Argo has dosed the first patients in phase 2 studies for paroxysmal nocturnal hemoglobinuria and IgA nephropathy. Earlier preclinical studies reported durable reductions in serum factor B and effective inhibition of the alternative complement pathway.
- Status: Argo is evaluating BW-40202 in phase 2 clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy. It is not approved for IgA nephropathy.
- Updated:
ARO-C3 (RNAi therapy targeting complement C3)
- Mechanism: an RNA interference (RNAi) drug given by injection that reduces levels of C3, a central hub in the complement cascade, thereby dampening all downstream complement activation.
- Key data: company-reported topline phase 1/2 results found that mean spot UPCR fell 41% from baseline by week 24 among 14 participants with IgA nephropathy. This was an open-label cohort without a placebo comparator, so the change cannot establish a treatment effect.
- Status: the phase 1/2 IgA nephropathy study is completed and no longer recruiting. The early results remain investigational and additional studies would be needed to define long-term efficacy and safety.
- Updated:
Ruxoprubart (NM8074; complement inhibitor)
- Mechanism: an intravenous complement inhibitor being studied for its effects on proteinuria and complement biomarkers in IgA nephropathy.
- Key data: a small open-label phase 2 study is designed to evaluate change in UPCR after 99 days of treatment, with secondary measures including eGFR, serum creatinine, hematuria, Bb, and sC5b-9.
- Status: the phase 2 study is listed as not yet recruiting. Ruxoprubart is not approved for IgA nephropathy.
- Updated:
Vensobafusp alfa (KP104; dual complement inhibitor)
- Mechanism: a biologic that targets both the alternative and terminal complement pathways, aiming to reduce complement-mediated kidney injury.
- Key data: a phase 2 basket study is evaluating safety, dosing, and proteinuria response. Initial interim results from the IgA nephropathy cohort are expected by the end of 2026.
- Status: Jasper completed enrollment of the initial IgA nephropathy cohort in October 2026. Vensobafusp alfa is not approved for IgA nephropathy.
- Updated:
3. Plasma-Cell / CD38-Directed Therapies
These drugs target plasma cells and other CD38-expressing immune cells that produce large amounts of Gd-IgA1 and related autoantibodies. The goal is to "turn off the factory" making the pathogenic IgA at its source.
Felzartamab (anti-CD38 monoclonal antibody)
- Mechanism: a monoclonal antibody that binds CD38 on plasma cells and other immune cells, leading to their depletion or functional silencing.
- Key data: in the peer-reviewed, randomized phase 2a IGNAZ study, 24-hour UPCR fell 29.5% from baseline in the nine-dose group versus 5.7% with placebo at month 9. In the nine-dose group, UPCR remained 44.5% below baseline at month 24, about 18 months after treatment ended; this was a within-group reduction, not a placebo-adjusted result.
- Status: felzartamab remains investigational. The global phase 3 PREVAIL study is recruiting. The phase 2 IGNAZ results do not establish long-term kidney-function benefit. A separate open-label phase 2 study plans to enroll about 25 participants; kidney biopsies at baseline, weeks 36, and 104 will assess mesangial IgA deposits, histology, and molecular changes. No results are available yet.
- Updated:
Mezagitamab (TAK-079, anti-CD38 monoclonal antibody)
- Mechanism: another anti-CD38 antibody that depletes or functionally suppresses CD38-expressing cells, aiming to reduce production of Gd-IgA1 and other pathogenic antibodies.
- Key data: in a phase 1b IgA nephropathy study, mezagitamab led to an approximately 55% mean reduction in proteinuria and an approximately 50% reduction in Gd-IgA1, with stable eGFR up to 18 months after the last dose. Hematuria resolved in many patients, and IgG levels recovered toward normal while disease-driving markers stayed suppressed.
- Status: a phase 3 program is underway; the early data support the idea that a time-limited course could have long-lasting effects. The A.M.IgA phase 3 trial plans to randomize about 297 participants to mezagitamab or placebo, with about 50 more in an open-label cohort. Treatment lasts 22 weeks followed by 82 weeks of observation; the primary endpoint is week 36 UPCR change, with kidney-function outcomes assessed through week 104. No new phase 3 efficacy results were presented.
- Updated:
CM313 (anti-CD38 monoclonal antibody)
- Mechanism: a subcutaneous CD38-targeting biologic intended to reduce disease-driving antibody production by targeting CD38-expressing immune cells.
- Key data: a phase 2 study is evaluating safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity in adults with primary IgA nephropathy.
- Status: the phase 2 study is listed as not yet recruiting. CM313 is not approved for IgA nephropathy.
- Updated:
4. Direct IgA and Other Novel Mechanism Therapies
Instead of broadly suppressing the immune system, these agents use newer mechanism-specific strategies. Some are designed to remove or break down disease-driving IgA directly, while others aim to change kidney inflammation, fibrosis, or metabolic stress through different pathways.
ARGX-121 (anti-IgA program)
- Mechanism: a one-armed IgG1 antibody with reduced effector function that binds circulating IgA in a pH-dependent manner and has increased affinity for the neonatal Fc receptor (FcRn), promoting IgA removal through FcRn-mediated recycling. It can also block IgA interaction with Fc-alpha receptor I (CD89).
- Key data: no IgAN patient efficacy results are available. The phase 2 randomized, placebo-controlled Verdant trial plans to enroll up to 120 adults; its primary endpoint is change in 24-hour UPCR at week 24.
- Status: argenx is advancing the Verdant phase 2 study in primary IgA nephropathy. ARGX-121 is not approved for IgA nephropathy.
- Updated:
Several newer phase 2 programs are also listed in trial registries even though their sponsors have not publicly described enough mechanism or efficacy data to place them more precisely in the categories above.
Civorebrutinib (EVER001; XNW1011; reversible BTK inhibitor)
- Mechanism: a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor intended to modulate B-cell receptor signaling and other immune pathways without directly depleting B cells.
- Key data: early clinical data have been reported in primary membranous nephropathy, but no patient efficacy data in IgA nephropathy have been publicly reported.
- Status: a phase 1b/2 open-label study in China includes an IgA nephropathy cohort. Civorebrutinib is not approved for IgA nephropathy.
- Updated:
STL303 (Sitala Bio)
- Key data: no patient efficacy data or detailed public mechanism information were identified in the current trial record.
- Status: an oral, randomized phase 2b study is registered in primary IgA nephropathy, with approximately 15 participants planned. The study is listed as not yet recruiting, and STL303 is not approved for IgA nephropathy.
- Updated:
FXS6837 (Fosun Pharma)
- Key data: no patient efficacy data or sufficiently detailed public mechanism information were identified in the current trial record.
- Status: a randomized phase 2b oral study is registered for primary IgA nephropathy and is listed as not yet recruiting. FXS6837 is not approved for IgA nephropathy.
- Updated:
SHR-2173 (Hengrui)
- Key data: no patient efficacy data or sufficiently detailed public mechanism information were identified in the current trial record.
- Status: a randomized phase 2 study of SHR-2173 injection is recruiting in China. It is not approved for IgA nephropathy.
- Updated:
BHV-1400 (Gd-IgA1 TRAP degrader)
- Mechanism: a "TRAP degrader" designed to bind Gd-IgA1 in the bloodstream and route it to the liver for clearance, while sparing normal immunoglobulins (IgA, IgG, IgE, IgM). This is a precision approach aimed at the root antibody driver of IgA nephropathy and IgA vasculitis.
- Key data: phase 1 and phase 1b data showed rapid, deep, and selective reductions in Gd-IgA1 while sparing other immunoglobulins. In early IgA nephropathy patient data, Biohaven reported mean Gd-IgA1 reductions of more than 60% within 48 hours and about 70% within one month, with preliminary associated changes in hematuria, spot UPCR, and eGFR. These patient data remain early and limited.
- Status: a phase 1 biomarker study in IgA nephropathy is recruiting, and a phase 3 study is listed but not yet recruiting. It is not approved for IgA nephropathy.
- Updated:
AP308 (engineered recombinant IgA protease)
- Mechanism: an engineered recombinant IgA protease designed to break down IgA directly, a different strategy from suppressing IgA production or blocking downstream complement activation.
- Key data: Alebund describes AP308 as a first-in-class IgA protease program aiming for a functional cure of IgA nephropathy.
- Status: the FDA cleared Alebund's IND application in September 2026. The program has not yet reported a first-in-human IgA nephropathy study or human efficacy data, and AP308 is not approved for IgA nephropathy.
- Updated:
AP303 (dual PPAR agonist)
- Mechanism: a dual PPAR agonist being developed to delay or halt chronic kidney disease progression across potential indications including diabetic kidney disease and IgA nephropathy.
- Key data: phase 1 studies in Australia and China showed favorable safety and tolerability in healthy volunteers and patients with diabetic kidney disease, with a dose-dependent pharmacodynamic signal. IgA nephropathy efficacy data are not yet available.
- Status: IND cleared by the U.S. FDA and China's NMPA; Alebund expects to conduct a basket phase 2 trial in diabetic kidney disease and IgA nephropathy patients in the second half of 2026. It is not approved for IgA nephropathy.
- Updated:
5. Gene and Other Advanced Therapies
These approaches try to protect or repair kidney tissue, re-program kidney cells, or alter immune pathways at a genetic level, with the goal of more durable disease control. They are much earlier in development than the approved medicines above, and early safety or biomarker findings should not be mistaken for proof that they can regenerate nephrons or reverse established kidney scarring.
ADR-001 (allogeneic adipose-derived mesenchymal stem-cell therapy)
- Mechanism: an intravenous cell therapy intended to provide immunomodulatory and paracrine effects that may reduce kidney injury and support tissue repair.
- Key data: a phase 1, open-label dose-escalation study enrolled nine adults with refractory IgA nephropathy. No severe adverse events were observed, and the primary safety and tolerability endpoints were met. Changes in urinary protein and kidney-injury markers were exploratory; the small, uncontrolled study could not establish efficacy or show that ADR-001 reverses fibrosis or regenerates nephron tissue.
- Status: the study was completed in Japan. ADR-001 is not approved for IgA nephropathy, and its role remains experimental.
- Updated:
PS-002 (AAV-based gene therapy delivering complement factor I)
- Mechanism: an adeno-associated virus (AAV) gene therapy that delivers the gene for complement factor I directly to podocytes (specialized kidney cells). By boosting local factor I, the therapy is intended to dampen complement activation in the glomerulus and protect the kidney from ongoing damage.
- Preclinical data: in animal models of IgA nephropathy, PS-002 reduced complement deposition, lowered markers of kidney injury, and improved structural features such as scarring, with sustained gene expression and favorable safety.
- Status: a phase 1/2 clinical trial in adults with primary IgA nephropathy has received regulatory clearance and is now enrolling, but human efficacy data in IgA nephropathy are not yet available.
- Updated:
WAL0921 (investigational therapy for proteinuric glomerular kidney diseases)
- Mechanism: an investigational intravenous therapy being studied across several proteinuric glomerular kidney diseases, including primary IgA nephropathy.
- Key data: a phase 2 basket study is evaluating safety, pharmacokinetics, pharmacodynamics, albuminuria, proteinuria, and eGFR measures in diabetic nephropathy and rare glomerular kidney diseases.
- Status: the phase 2 trial is recruiting. WAL0921 is not approved for IgA nephropathy.
- Updated:
Page updated 15 Nov 2026, 04:21 UTC